CD274 and pancreatic neoplasm: In addition, NF-κB increasingly bound a potential binding site in the CD274 promotor in TNF-α-treated PDAC cells, as determined using a chromatin immunoprecipitation assay, whereas NF-κB binding to the potential binding site in the CD274 promoter was reduced anti-TNFR2-treated pancreatic cancer cells and in KPC/Panc02-Tnfr2 knockdown cells (figure 4D and online supplemental figure 7B).